I received this comment left on my Blog:
At 2:04 PM, Brooke has MS said… (((hugs)))
Love, Lauren
A very proud member of www.MSpatientsforchoice.org
Discussing all aspects of Multiple Sclerosis, various treatments, including accurate information regarding Tysabri.
AND I AM TELLING YOU I'M NOT GOING (YOU'RE GONNA LOVE ME)
By Jennifer Holliday (From "Dreamgirls")
And I am telling you
I'm not going.
You're the best man I'll ever know.
There's no way I can ever go,
No, no, no, no way,
No, no, no, no way I'm livin' without you.
I'm not livin' without you.
I don't want to be free.
I'm stayin',
I'm stayin',
And you, and you, you're gonna love me.
Ooh, you're gonna love me.
And I am telling you
I'm not going,
Even though the rough times are showing.
There's just no way,
There's no way.
We're part of the same place.
We're part of the same time.
We both share the same blood.
We both have the same mind.
And time and time we have so much to share,
No, no, no,
No, no, no,
I'm not wakin' up tomorrow mornin'
And findin' that there's nobody there.
Darling, there's no way,
No, no, no, no way I'm livin' without you.
I'm not livin' without you.
You see, there's just no way,
There's no way.
Tear down the mountains,
Yell, scream and shout.
You can say what you want,
I'm not walkin' out.
Stop all the rivers,
Push, strike, and kill.
I'm not gonna leave you,
There's no way I will.
And I am telling you
I'm not going.
You're the best man I'll ever know.
There's no way I can ever, ever go,
No, no, no, no way,
No, no, no, no way I'm livin' without you.
Oh, I'm not livin' without you,
I'm not livin' without you.
I don't wanna be free.
I'm stayin',
I'm stayin',
And you, and you,
You're gonna love me.
Oh, hey, you're gonna love me,
Yes, ah, ooh, ooh, love me,
Ooh, ooh, ooh, love me,
Love me,
Love me,
Love me,
Love me.
You're gonna love me.
FDA regulators need to balance patients' access to therapies with ensuring the safety of drugs. The consequences of poor decisions can be grim: Promote access at the expense of safety, and a dangerous product can cause incalculable harm; over-emphasize safety at the expense of access, and patients suffer from the absence of life-saving, life-enhancing medications.
In recent decisions on the post-approval risk management of two drugs, Tysabri and Rituxan, FDA regulators have failed to be internally consistent - and thereby sowed confusion among patients, physicians and drugmakers.
In late 2004, Tysabri became only the sixth medication approved -- and the first in several years -- for the treatment of multiple sclerosis, a common and debilitating (and often heart-breaking) autoimmune disease that affects the central nervous system. The drug's testing in clinical trials yielded impressive results -- the frequency of clinical relapses reduced by more than half - and induced the FDA to grant accelerated approval.
In early 2005, however, with several thousand patients already being treated with Tysabri, it was discovered that three had contracted progressive multifocal leukoencephalopathy (PML), a rare and often fatal neurological disorder caused by a virus. (Because the drug suppresses certain components of the immune response, regulators, clinicians and the product's developers had from the beginning been sensitive to the possibility of infections as a side effect.) Immediately -- some would say prematurely -- the manufacturers voluntarily halted production and distribution and withdrew Tysabri from the market.
An uproar ensued. Self-appointed "safety watchdogs" cited Tysabri as yet another case of an allegedly harmful, inadequately tested product finding its way onto the market. Conversely, MS patients and neurologists were bitterly disappointed at being deprived of what for some was an almost miraculous therapy -- and of the ability to make their own informed decisions about options for treatment. After the analysis of new safety data, an FDA advisory committee recommended Tysabri's return to the market with revised labeling.
However, the FDA went far beyond modifying the labeling to contain more prominent warnings to reflect new knowledge of the drug's side effects (which would, in my view, have been sufficient) and insisted instead on a baroque risk management action plan (RiskMAP) that imposes onerous restrictions on the use of Tysabri. These include limited distribution and additional education and monitoring requirements for patients, prescribers, pharmacies and infusion centers.
RiskMAPs were originally conceived by the FDA as a fail-safe for the small number of products that offer unique benefits but also carry atypical and significant risks. Less intrusive elements of these plans might include special labeling and more intensive education about product use and precautions, but the FDA adopted far more obtrusive restrictions and requirements such as mandatory enrollment in patient registries, controlled distribution, and prescribed behavior (such as the use of two kinds of contraception in the case of one drug) by patients.
Other products subject to such regimes include Accutane, used to treat severe recalcitrant nodular acne; and Thalomid, for multiple myeloma and the cutaneous manifestations of leprosy. Like Tysabri, both drugs provide unique and significant benefits to their users that are not offered by other medications but have severe, rare side effects. Accutane and Thalomid are known potent teratogens - substances capable of interfering with the normal development of a fetus and causing birth defects or the loss of a pregnancy or other complications - and therefore must be avoided by women who are or who may become pregnant. But the exhaustive (and exhausting) list of requirements for physicians, pharmacists and patients makes one wonder whether the next FDA safety innovation will be a mandatory live-in nanny to monitor patients' compliance with the RiskMAP.
The RiskMAPs for all three drugs are excessively restrictive, seemingly more appropriate for weapons-grade plutonium than a pharmaceutical. Although health practitioners and patients certainly need complete and accurate information about a product's potential risks, regulators should enable patients and physicians to make informed decisions within an expanding universe of therapies, not create an obstacle course between the sick and their medications.
Patients, physicians, pharmacists and drugmakers conform to the RiskMAPs because they have no choice: The FDA is the only game in town, and playing along is the only way that all these stakeholders can variously receive, prescribe, dispense and manufacture the medications.
And that brings us to Rituxan, a treatment for rheumatoid arthritis and certain kinds of lymphomas. Like Tysabri, it acts by suppressing elements of the immune system and also has been linked to PML; there have been 23 confirmed cases of PML in patients receiving Rituxan for the approved indication of non-Hodgkin's lymphoma and, most recently, two in patients being treated experimentally for systemic lupus erythematosus ("lupus").
But unlike Tysabri, Rituxan has never been subject to a RiskMAP. And in spite of the new cases of PML in patients with lupus - and the fact that Rituxan also is under consideration for treatment of MS - the FDA was content merely to update the package insert for Rituxan.
Multiple sclerosis patients on Tysabri are right to feel discriminated against. While they and their healthcare providers must navigate a veritable RiskMAP maze to obtain and maintain access to their approved medication, patients taking Rituxan - which carries a similar risk of PML - need not.
I am not arguing here that Rituxan should be subject to a more restrictive RiskMAP or that Tysabri deserves a less restrictive one (although I favor the latter) -- merely that the FDA's inconsistency sends mixed signals and creates uncertainty, the bane of patients, physicians and drug companies alike. Are some medications more worthy of patient and physician discretion than others even if they carry the same risk? Are some patients more deserving than others of the right to make their own decisions about risk and benefit?
Even under ideal circumstances, the regulation of drugs involves complex risk-benefit calculations performed with incomplete and evolving data. We cannot expect perfection from our regulators, but we can demand sufficient consistency to make the process transparent to patients, health practitioners and drug developers.
Dr. Miller, a physician and a fellow at the Hoover Institution and Competitive Enterprise Institute, headed the FDA's Office of Biotechnology from 1989 to 1993. His most recent book is "The Frankenfood Myth."
"Rowling hits out at NHS ban on costly MS treatment for Scots
http://story.100.com/?rid=7145354&cat=a1e025da3c02ca7c
Additionally, your viewers/readers might like to know that they can watch the Scottish Parliament debate live, Thursday, March 1st, at about Noon ET (9:00 am PT, and 7:00 am in Alaska and Hawaii) at http://www.holyrood.tv/popup.asp?stream=http://vr-sp-archive.lbwa.verio.net/archive/members_010307.wmv (Click on "Play Live stream" at the top of the page and/or then click "Launch in external player").
The Members of the Scottish Parliament will be debating S2M-5305, sponsored by MSP Tricia Marwick, on "Tysabri for People with MS.
"S2M-5305 Tricia Marwick: Tysabri for People with MS—That the Parliament deplores the decision by the Scottish Medicines Consortium not to recommend that Tysabri be prescribed to people with multiple sclerosis (MS); notes that, for a small number of those with the most aggressive from of relapsing-remitting MS for whom existing treatments do not work, Tysabri represents the only treatment available; notes that Tysabri is prescribed in Germany, Ireland and the United States of America but not in Scotland, which has the highest rate of MS in the world, and urges NHS boards in Scotland to allow the prescribing of Tysabri which had been described by Dr Gavin Giovannoni, of the National Hospital for Neurology and Neurosurgery in London, as the most significant advance in MS treatment for nearly a decade. Supported by: Christine Grahame, Ms Sandra White, Stewart Stevenson, Mr Kenny MacAskill, John Scott, Frances Curran, Carolyn Leckie, Richard Lochhead, Murray Tosh, Mr Stewart Maxwell, Mr Adam Ingram, Mike Pringle, Robin Harper, Brian Adam, Bruce Crawford, Fiona Hyslop, Alex Neil, Mr John Swinney, Eleanor Scott, John Swinburne, Mr Ted Brocklebank, Michael Matheson
There are two competing motions, which differ in various respects:
S2M-5306 Ms Rosemary Byrne: Quality of Life for MS sufferers—That the Parliament is concerned that the Scottish Medicines Consortium (SMC) has decided not to recommend the drug Tysabri as a treatment for multiple sclerosis, despite it being highly effective for certain patients, leading to a 60% to 70% reduction in relapses; notes that Tysabri is a licensed drug approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and SMC only provides advice to NHS boards and their area drug and therapeutics committees across Scotland; notes also that health professionals are expected to take due account of this recommendation when exercising their clinical judgment but that this recommendation does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, and calls on all NHS boards to acknowledge that clinicians must be able to prescribe this treatment where they believe there is a clinical need, regardless of SMC advice to them. Supported by: Tommy Sheridan, John Scott, Mr Adam Ingram, Carolyn Leckie, Murray Tosh, Robin Harper, Eleanor Scott, John Swinburne, Mr David Davidson, Christine Grahame, Mr Ted Brocklebank, Michael Matheson
S2M-5307 John Scott: Support for Prescribing of Tysabri for MS Sufferers in Scotland—That the Parliament notes the decision of the Scottish Medicines Consortium (SMC) that Tysabri should not be prescribed on the NHS; further notes that Scotland has the highest proportion of sufferers from multiple sclerosis in the world, that the SMC accepts that the clinical case for the use of Tysabri was sound and that the recommendation not to prescribe it on the NHS was taken on purely financial grounds, and therefore urges that this decision by the SMC be overturned and that Tysabri be made available on the NHS. Supported by: Mrs Nanette Milne, Ms Rosemary Byrne, Tommy Sheridan, Mr Adam Ingram, Dave Petrie, Murray Tosh, Rosie Kane, Robin Harper, Carolyn Leckie, Phil Gallie, Derek Brownlee, Mr Jamie McGrigor, Alex Johnstone, Alex Neil, Eleanor Scott, John Swinburne, Margaret Mitchell, Mr David Davidson, Bruce Crawford, Ms Sandra White, Christine Grahame, Bill Aitken, Lord James Douglas-Hamilton, Patrick Harvie, Fiona Hyslop, Mr Ted Brocklebank, Michael Matheson
A a very distinguished patient advocate (D.K.) and member of the website http://www.MSPatientsForChoice.org/, on Monday (2/26), emailed all of the co-sponsors of the three motions, providing them with links to our website and more information on the benefits of Tysabri. Also emailed were every other member of the Parliament, urging them to support the availability of Tysabri in Scotland. All were provided with the recent article about the Salt Lake City MS patient who was able to get out of his wheelchair and shovel snow (http://www.ksl.com/?nid=148&sid=909753), (The gentleman in the video is Darren - who posts comments occasionally on my Blog - waiving wildly to Darren :) I left a comment on that story too-lol) as well links to the Tysabri patient progress reports posted on our website http://www.mspatientsforchoice.org/progress.htm. Various benefits of Tysabri in terms of cost savings were also brought to their attention, including reduced hospitalizations and improved quality of life (possibly permitting some patients to return to work and pay taxes).
MS patients around the world (and specifically those of us in the US) are hopeful that the support and publicity from JK Rowling will help push this to victory. It would set an excellent precedent for the pending decision by NICE for coverage of Tysabri in the rest of the UK.
Thank you for all you do for MS sufferers, and thank you for your attention to this matter. Very truly yours, Lauren Roberts (MS patient for 31 yrs. & current Tysabri user) A very proud member of: http://www.MSPatientsForChoice.org/"
Crippy, might I suggest you work closely with the UK MS Trust as they are very pro-Tysabri, and see if you can get in contact with Ms. Rowling to engage her support before N.I.C.E.'s ruling in the very near future, as well as rally British MS patient support for Tysabri. If nothing else, perhaps you can help convince N.I.C.E. to at least pay for Tysabri at the same rate it pays for Avonex, Rebif, Betaseron and Copaxone, and then British MS charities or other charities/individuals can help pick up the difference. Perhaps even some English employers can help subsidize the marginal additional cost of Tysabri to keep a valued employee?
One last thing crippy, do note dearheart, that you stated "(the national institute for clinical excellence) has refused funding in scotland", which is incorrect - the SMC refused funding for Tysabri in Scotland, not N.I.C.E......which has yet to rule for England and Wales.
Good luck in your fight-I'll be cheering you on from across the pond (as many of us will too!)
A special hug for my new "ding-bat" and awesome photographer friend, Gretchen - heehee.
And oh my gosh, I almost forgot - I posted a comment Thursday night on a young MS'ers Blog (Live Journal) that was terrified to start Tysabri http://community.livejournal.com/ms_support/294930.html and I received this reply from her yesterday!...Subject: Re: Tysabri Information OMG your comment has completely uplifted my spirits about this, thank you so much.It's one thing to learn all the facts,a nd then another to learn the facts that come from MS patients, and not just the med complanies. Overall I really want to try Tysabri, it's just the fear of PML that has made me nervous. But learning this info and being able to look into it much more has really helped. I'm at a stage where, there really isn't much else I can do, and so I feel better to take the leap with some more knowledge into what I'm really doing. thank you so much!♥ nessa
Sweet! I'm so happy she's no longer terribly afraid of Tysabri :) .... Can I get an "Amen" or a "Wooooohooooo" from the choir? LOL
(((hugs)))
Love, Lauren
A very proud member of www.MSpatientsforchoice.org
Hi lauren,
My name is Brooke and I am 22 I was dx almost 3 years ago and I have already taken Rebif(which caused bad dreams) Copaxone(I thought was great but a MRI showed different) I am getting my second infusion of Tysabri April 2nd. i am not noticing a huge difference....Except i am so tired...I dont know if it is the Timechange or the weather getting hotter but I havent noticed alot of difference. I am wondering if you are still very happy with Tysabri? Do you worry about PML? Sorry if you dont want to answer that. But I am really scared!
Brooke, dearheart....please write to me and give me your email address so that I can correspond with you and try to calm your fears, okay? My email address is LGLBGL2003@AOL.COM.
If you feel uncomfortable writing to me, I'll try to help you here:1. First, take a couple of deep breaths and calm yourself down, there is no need to panic and no need to be scared, stressing like this might lead to a relapse, and none of us want that, right? Right! :)
2. Give your body a chance for Tysabri to work.., and give Tysabri an opportunity to get a handle on your MS - in my opinion, it might take up to approximately 2-5 infusions to accomplish this - (from what you've stated above - and I'm not a dr. - it would seem to me that you have a very active and aggressive form of MS), but in my opinion, you are on the best and most superior MS med we have available to us to fight our MS (Tysabri). Remember honey - you did not develop all your MS symptoms in just 30 days, so you will more than likely need more than 30 days (i.e., just 1 Tysabri infusion every 4 weeks), before you notice any improvements. Also, remember patience is a virtue ;)
3. Being tired is one of the side effect of Tysabri - many Tysabri patients have reported this to me, but they also tell me it passes in time, and some say after their next infusion, they feel less fatigued or not tired at all! Besides, if that is a side effect of Tysabri - you know it's working... heck - I'll take a power nap to relieve the fatigue over having to deal with another relapse any day! :)
4. I am still EXTREMELY HAPPY with Tysabri! :D
5. Brooke, I'm not worried in the least about PML. Experts believe it's caused by a dimished (very low) immune system...and I'm not on any other strong immune suppressants or immunomodulators (like the ABCR's), which could lower my immune system and cause PML. I'm just on Tysabri :) Furthermore, MS patients in general have a very strong and highly active immune system to begin with - which is why we keep having relapses! ;)
Dearheart, you are the same age I was when I was first dx'd with MS - I am now 52 (eek!), so you are young enough to be my daughter or my little sister. And if this were the case, I would sit you down, wrap my arms around you and give you the biggest hug you ever had - and look right into your eyes and tell you firmly but gently the God's honest truth, "It is going to be okay - you have nothing to fear but fear itself - and you are not alone."
And that goes for all of you out there too! ... (Hmmm, This makes me wonder if I'm somehow earning the nickname of "Mother Tysabri" ? ... laughing at myself).